Key points
- Revenue increased by 41% to AUD 5,333,849
- Loss from ordinary activities decreased by 29% to AUD 3,513,587
- John Kelly resigned as Managing Director, Cheri Walker appointed Interim CEO
- Annual General Meeting scheduled for 5 November 2026
- Successful capital raising activities with net funds raised totaling AUD 4,059,742
Full summary
Atomo Diagnostics Ltd. has released its 2026 Annual Report, detailing financial results for the period ended 30 June 2026. The company reported a significant 41% increase in revenue from ordinary activities, reaching AUD 5,333,849, compared to the previous period. Despite the revenue growth, the loss from ordinary activities after tax decreased by 29% to AUD 3,513,587. Total comprehensive loss from the period also decreased by 30% to AUD 3,423,464. The company experienced a net tangible asset per ordinary security of AUD 0.72. Notably, there were no dividends paid, recommended, or declared during the financial period. The company also announced the resignation of John Kelly as Managing Director, with Cheri Walker appointed as Interim Chief Executive Officer. The Annual General Meeting is scheduled for 5 November 2026. The report also highlights the company's strategic initiatives, including the expansion of its Point-of-Care technology and the growing momentum in HIV self-testing programs. Additionally, the company successfully raised AUD 4,059,742 through capital raising activities, which will be used to expand its product portfolio and technology platforms.
Guidance
Revenue increased by 41% to AUD 5,333,849; Loss from ordinary activities decreased by 29% to AUD 3,513,587
Outlook
Atomo Diagnostics Ltd. is focused on expanding its Point-of-Care technology, particularly in the US market, and growing its emerging development services business. The company aims to improve operating margins by bringing critical operations in-house and enhancing manufacturing processes.